肿瘤细胞治疗研究
英文原题：Role of soluble human leukocyte antigen-G in virus-associated cancers: A focused minireview.
可溶性人类白细胞抗原-G（sHLA-G）是一种非经典主要组织相容性复合体I类分子，其产生途径包括膜结合型异构体的蛋白水解切割或可溶性异构体的分泌。
可溶性人类白细胞抗原-G（sHLA-G）是一种非经典主要组织相容性复合体I类分子，通过膜结合型异构体的蛋白水解切割或可溶性异构体的分泌产生。sHLA-G发挥强效免疫抑制作用，通过抑制NK 细胞、细胞毒性T淋巴细胞及其他免疫效应细胞的细胞毒活性，促进肿瘤微环境中癌细胞的免疫逃逸。新出现的证据表明，sHLA-G的异常表达促进病毒相关恶性肿瘤的肿瘤进展，包括人乳头瘤病毒驱动的宫颈癌和乙型肝炎病毒/丙型肝炎病毒相关的肝细胞癌。sHLA-G可在包括血浆和血清在内的多种体液中检测到，突显其作为诊断和预后生物标志物以及治疗靶点的潜力。
Soluble human leukocyte antigen-G (sHLA-G), a non-classical major histocompatibility complex class I molecule, arises either through proteolytic cleavage of membrane-bound isoforms or via secretion of soluble isoforms. sHLA-G exerts potent immunosuppressive effects, facilitating immune escape of cancer cells within the tumor microenvironment by inhibiting the cytotoxic activity of natural killer cells, cytotoxic T lymphocytes, and other immune effectors. Emerging evidence indicates that aberrant expression of sHLA-G contributes to tumor progression in virus-associated malignancies, including human papillomavirus-driven cervical cancer and hepatitis B virus/hepatitis C virus-related hepatocellular carcinoma. sHLA-G is detectable in various body fluids, including plasma and serum, highlighting its potential as both a diagnostic and prognostic biomarker as well as a therapeutic target.
MEMBER ACCOUNT
登录成功会直接打开下一页。
